Head to Head Analysis: Rubius Therapeutics (NASDAQ:RUBY) & Its Rivals

Rubius Therapeutics (NASDAQ: RUBY) is one of 114 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Rubius Therapeutics to related businesses based on the strength of its institutional ownership, risk, profitability, dividends, earnings, analyst recommendations and valuation.

Valuation & Earnings

This table compares Rubius Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Rubius Therapeutics N/A -$89.19 million -7.28
Rubius Therapeutics Competitors $897.64 million $190.37 million -1.39

Rubius Therapeutics’ rivals have higher revenue and earnings than Rubius Therapeutics. Rubius Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Rubius Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rubius Therapeutics N/A N/A N/A
Rubius Therapeutics Competitors -5,144.22% -64.24% -27.96%

Institutional and Insider Ownership

87.1% of Rubius Therapeutics shares are owned by institutional investors. Comparatively, 48.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 58.4% of Rubius Therapeutics shares are owned by insiders. Comparatively, 16.4% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Rubius Therapeutics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rubius Therapeutics 0 0 4 0 3.00
Rubius Therapeutics Competitors 842 2786 6090 262 2.58

Rubius Therapeutics presently has a consensus target price of $37.00, suggesting a potential upside of 123.84%. As a group, “Biological products, except diagnostic” companies have a potential upside of 38.11%. Given Rubius Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Rubius Therapeutics is more favorable than its rivals.

Summary

Rubius Therapeutics beats its rivals on 8 of the 12 factors compared.

Rubius Therapeutics Company Profile

Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. It is also developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. In addition, the company is developing RTX-T1D for treating type 1 diabetes; and RTX-PV for treating pemphigus vulgaris. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.